<DOC>
	<DOC>NCT02755935</DOC>
	<brief_summary>To evaluate performance outcomes in patients implanted with the Cochlear Nucleus CI532 electrode array.</brief_summary>
	<brief_title>CI532 - Early Experience Study</brief_title>
	<detailed_description>To compare speech perception and audiometric outcomes in patients implanted with the Cochlear Nucleus CI532 electrode array at 3 months postactivation with their best preoperative hearing status.</detailed_description>
	<mesh_term>Hearing Loss</mesh_term>
	<mesh_term>Hearing Loss, Sensorineural</mesh_term>
	<mesh_term>Hearing Loss, Bilateral</mesh_term>
	<criteria>Medical and audiological candidate for a CI532 cochlear implant per commercially approved, age appropriate, FDA indications Postlinguistically deafened Ability to complete age appropriate testing Previous cochlear implantation in the ear to be implanted Prelinguistically deafened (onset of hearing loss at less than two years of age) Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array Diagnosis of retrocochlear pathology Diagnosis of auditory neuropathy Unrealistic expectations on the part of the subject regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure and use of the prosthetic device Unwillingness or inability to comply with all investigational requirements Additional cognitive handicaps that would prevent participation on all study requirements</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>